Sunshine Guojian Pharmaceutical Shanghai
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors.
Launch date
Employees
Market cap
CAD2.1b
Enterprise valuation
CAD1.9b (Public information from Sep 2024)
Share price
CNY18.31 688336.SS
Shanghai Shanghai (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 655m | 929m | 825m | 1.0b | 1.3b | 1.3b | 1.5b |
| % growth | (44 %) | 42 % | (11 %) | 23 % | 25 % | 6 % | 14 % |
| EBITDA | (97.3m) | 52.2m | 127m | 324m | 342m | 394m | 433m |
| % EBITDA margin | (15 %) | 6 % | 15 % | 32 % | 27 % | 30 % | 28 % |
| Profit | (217m) | 18.1m | 49.3m | 295m | 320m | 281m | 331m |
| % profit margin | (33 %) | 2 % | 6 % | 29 % | 25 % | 21 % | 22 % |
| EV / revenue | 23.2x | 12.3x | 9.5x | 13.7x | 8.3x | 7.8x | 6.8x |
| EV / EBITDA | -156.1x | 219.2x | 61.5x | 42.8x | 30.5x | 26.5x | 24.1x |
| R&D budget | 340m | 455m | 313m | 282m | - | - | - |
| R&D % of revenue | 52 % | 49 % | 38 % | 28 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Recent News about Sunshine Guojian Pharmaceutical Shanghai
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
